Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2014 | Lymphoma Microenvironment: biology and therapy (part 2/3)

John Gribben and Randy Gascoyne • 5 Sep 2014
iwNHL 2014
Non-Hodgkin Lymphoma

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumor biology and therapy. Improved trial designs, consideration of clinical variables and use of higher resolution approaches are recommended to overcome current research limitations in this field.

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma
2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
The future of CLL therapy
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Randy Gascoyne

Lymphoma microenvironment: biology and therapy (part 1/3)
5:59
Lymphoma microenvironment: biology and therapy (part 1/3)
John Gribben et al. • 5 Sep 2014
Lymphoma microenvironment: biology and therapy (part 3/3)
7:27
Lymphoma microenvironment: biology and therapy (part 3/3)
John Gribben et al. • 5 Sep 2014
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
9:18
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
Kieron Dunleavy et al. • 3 Oct 2015
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 1 meeting highlights
12:10
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 1 meeting highlights
John Gribben et al. • 5 Sep 2014

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals